WLF: A No-Risk Ad is a Good Ad Posted: August 15, 2006 According to a recent story in BrandWeek, "The Washington Legal Foundation, a conservative think tank, filed a petition with the Food and Drug Administration Monday [August 7, 2006], challenging the FDA's right to send warning letters to drug companies whose advertising it finds misleading." However, the challenge is really being made against FDA's rules requiring that direct-to-consumer (DTC) ads include "fair balance" -- ie, statements about major risks along with the benefit statements -- in the creative part of the ads. In today's post to Pharma Marketing Blog, I contradict some of WLF's "wooly-headed" thinking on the issue of risk in print drug ads with some inconvenient facts rather than convenient conjecture. See today's post to Pharma Marketing Blog. For more posts in related topic areas, see: Direct-to-Consumer (DTC) Advertising Drug Safety FDA Legal/Regulatory If you wish to receive notice by email whenever a post is made to Pharma Marketing Blog, please subscribe. Enter your Email Address | Return to Pharma Marketing Blog Topics |